Expression of Macrophage MARCO Receptor Induces Formation of Dendritic Plasma Membrane Processes*

Timo Pikkarainen, Annika Brännström, and Karl TryggvasonDagger

From the Division of Matrix Biology, Department of Medical Biochemistry and Biophysics, Karolinska Institutet, S-171 77 Stockholm, Sweden

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

MARCO is a novel macrophage-specific receptor structurally related to macrophage class A scavenger receptors. It is constitutively expressed in macrophages of the marginal zone of the spleen and in lymph nodes and is up-regulated in other tissues during systemic bacterial infections. In this study, we show that ectopic expression of MARCO in cell lines such as Chinese hamster ovary, HeLa, NIH3T3, and 293 induces dramatic cell shape changes. Typically these changes include formation of large lamellipodia-like structures and of long dendritic processes. The morphological changes are accompanied by disassembly of actin stress fibers and often also by complete loss of focal adhesions. The MARCO-induced changes are dependent on cell adhesion and are inhibited, but not completely abolished, when the cells are plated on fibronectin-coated surfaces. Similarly, a dominant-negative mutant of the Rho family GTPase Rac1 partially inhibited the morphogenic effects of MARCO in Chinese hamster ovary cells, whereas a dominant-negative form of a related protein, Cdc42, did not. Expression studies with a variety of truncated MARCO forms indicated that the proximal segment of the cysteine-rich domain V is important for the morphoregulatory activity. The results indicate that expression of MARCO has a direct effect in generating the phenotype of activated macrophages necessary for the trapping and removal of pathogens and other foreign substances.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Macrophages are monocyte-derived cells that upon activation acquire phagocytotic activity for pathogens, capability for antigen presentation to lymphocytes, and the ability to contribute to tissue repair by removing dead and damaged tissue (1, 2). Resting macrophages are fusiform or stellate in shape, whereas activated macrophages have extensive pseudopodia as well as short microvilli and lamellipodia (1). The protrusions are apparently important for phagocytosis, as they extend around the pathogens prior to their engulfment.

MARCO1 is a macrophage receptor (3) constitutively expressed in a subpopulation of macrophages in the marginal zone of the spleen and in the medullary cord of lymph nodes, i.e. regions where macrophages are actively engaged in the removal of pathogens and other foreign substances from the blood and lymph fluid. This has implied a direct role for MARCO in the removal of pathogens. This assumption is supported by studies showing that COS, CHO, and fibroblast cells, which normally do not bind bacteria, acquire binding activity for both Gram-positive and Gram-negative bacteria following transfection and expression of MARCO (3). Furthermore, it has been shown that during systemic bacterial infections, expression of MARCO is induced in macrophages located in other tissues, such as liver and lung (4). Together, these data strongly indicate a role for MARCO in the host defense against microorganisms.

MARCO is structurally related to the macrophage class A scavenger receptors (MSR-A) (5, 6). However, despite structural similarities, the pattern of expression is different as MSR-A receptors are constitutively expressed by macrophages in all tissues. All these receptors are homotrimeric proteins with a short cytoplasmic domain, a single transmembrane domain, and a large extracellular part. The extracellular portion of MSR-A has both a triple helical coiled coil and collagenous structures, whereas MARCO contains only a long collagenous triple helix. Additionally, both MARCO and MSR-AI have a C-terminal cysteine-rich domain composed of about 100 amino acid residues, whereas MSR-AII lacks this domain completely (3, 5-7). The bacteria-binding region of MARCO has been localized to this C-terminal region (7). MSR-A has been shown to bind a wide variety of ligands, such as modified low density lipoprotein and bacterial surface components (8-11). Studies with MSR-A knock-out mice have shown that this receptor contributes to the formation of atherosclerotic lesions and plays a role in host defense against pathogens (12, 13), suggesting that the binding activities of MSR-A shown in vitro have physiological significance. In addition, MSR-A has been implicated in macrophage adhesion (14).

In our studies on MARCO function we observed that expression of this protein in many different cell lines resulted in dramatic cell shape changes. Typically, these changes include formation of large lamellipodia-like structures, as well as of extensive plasma membrane processes. By expressing various truncated forms of MARCO, we show that a segment in the C-terminal cysteine-rich domain is crucial for this activity. The MARCO-induced morphological changes are accompanied by rearrangement of the actin cytoskeleton. Furthermore, they are inhibited, but not completely abolished, when CHO cells are plated on fibronectin-coated surface or when MARCO is co-expressed with a dominant-negative form of the small GTPase Rac1. The morphoregulatory activity of MARCO may contribute to efficient removal of pathogens from the blood and lymph fluids.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Materials-- Cytochalasin D, butanedione monoxime, streptavidin-agarose, p-phenylenediamine, vitronectin, and fibronectin were obtained from Sigma. Laminin-1 was a kind gift from J. Engel (Biozentrum, Basel, Switzerland). Rat anti-mouse MARCO monoclonal antibodies were kindly provided by L. van der Laan and G. Kraal (Free University, Amsterdam, The Netherlands). Mouse anti-paxillin monoclonal antibody (clone 349) was purchased from Transduction Laboratories, and mouse anti-Myc antibody (clone 9E10) was from Santa Cruz Biotechnology. Secondary antibodies were obtained from Dako. Rhodamine-conjugated streptavidin was obtained from Jackson ImmunoResearch. Sulfo-NHS-biotin was from Pierce, and rhodamine-conjugated phalloidin was from Molecular Probes. Plasmid pEA1 encoding a full-length cDNA for the human asialoglycoprotein receptor H1 subunit and rabbit antiserum against a purified human asialoglycoprotein receptor were kind gifts from M. Spiess (Biozentrum, Basel, Switzerland). The expression plasmids pEXV-Myc Cdc42N17 and pEXV-Myc Rac1V12N17 were generously provided by A. Hall (University College, London, UK).

Expression Constructs and Transient Transfections-- All MARCO expression constructs were cloned into the mammalian expression vector pcDNA3 (Invitrogen). DNA manipulations were carried out using established molecular biological methods. Truncated forms M-419, M-436, and M-441 of murine MARCO were created from the full-length cDNA (3) by replacing the region encoding the C-terminal part of MARCO by fragments encoding a stop codon after the codon for serine 419, valine 436, or glutamate 441, respectively. Version M-419 is a truncated form completely lacking the C-terminal cysteine-rich domain (domain V), whereas versions M-436 and M-441 also contain short segments of this domain. Constructs "Bst" and "Eco" encode proteins with large internal deletions. The version Bst lacks the last 40 Gly-X-Y triplets of the 270-residue long collagenous domain, whereas Eco encodes a form, whose extracellular domain is composed of the first four residues of the spacer domain, the last 22 triplets of the collagenous domain, and an intact domain V. The construct "Del 422-433" encodes a version of MARCO that lacks the first 12 residues of domain V (residues 422-433). The various constructs are summarized in a schematic form in Fig. 4. The cDNA encoding the full-length human asialoglycoprotein receptor was removed from the pEA1 vector and inserted in the pcDNA3 vector.

Cells were transfected using the calcium-phosphate method. 20 µg of DNA was used per 100-mm dish. In co-transfections, 10 µg + 10 µg of the expression plasmids was used. Precipitates were incubated on cells overnight, and cells were seeded on glass coverslips 24 h after transfection. In some experiments, transfected cells were taken into suspension 24 h after transfection and were incubated in suspension for 12-16 h before plating on glass coverslips. Suspension culture plates were prepared by coating 100-mm culture dishes with a layer of 1% agarose sterilized by boiling for 30 min. The agarose layer was allowed to harden, and the dishes were equilibrated by two overnight incubations with 10 ml of Dulbecco's minimum essential medium, 10% FCS.

When examining cell morphology 5 min after plating, cells grown in suspension were plated directly from the suspension culture onto coverslips. Alternatively, cells were collected by centrifugation, washed, and resuspended in Dulbecco's minimum essential medium, 1% bovine serum albumin, 20 mM Hepes, pH 7.4, before plating on coverslips. Cells were plated either on uncoated coverslips or on coverslips coated with FCS, fibronectin, laminin-1, or vitronectin. When coating with FCS, a 10% solution was incubated on coverslips for 30 min at room temperature. Under these conditions, vitronectin is the primary extracellular matrix (ECM) component adsorbed to the glass (15). When coating with purified ECM components, a 40 µg/ml solution was incubated on coverslips overnight at 4 °C. Before plating cells, coverslips were further incubated in 2% bovine serum albumin in PBS for 2 h at 37 °C.

Cell Surface Labeling and Streptavidin Precipitation-- Two sparse 100-mm dishes of CHO cells were transfected per each construct. Cells were pooled to one dish 24 h after transfection, and they reached about 50% confluency 40 h post-transfection. At this time point, monolayers were rinsed twice with ice-cold PBS, once with ice-cold Hepes-buffer, pH 8.0, containing 150 mM NaCl, 0.2 mM CaCl2, and 0.2 mM MgCl2 and then cooled in this buffer for 10 min in an ice-water bath. Cell-surface proteins were labeled by incubating cells with sulfo-NHS-biotin (0.5 mg/ml in Hepes buffer, 3 ml/plate) for 30 min in an ice-water bath with gentle intermittent agitation. Monolayers were then washed twice with ice-cold Hepes buffer containing 100 mM glycine and further incubated in the same solution for 15 min in an ice-water bath. Cells were lysed by adding 1 ml of ice-cold RIPA buffer (50 mM Tris-HCl, pH 7.4, 150 mM NaCl, 5 mM EDTA, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% SDS, 10 µg/ml aprotinin, 1 mM phenylmethylsulfonyl fluoride, 1 mM N-ethylmaleimide), and proteins were solubilized by incubating the plates on ice for 30 min with constant agitation. Lysed cells were then scraped with a cell scraper, transferred to microcentrifuge tubes, and further incubated on ice for 30 min with mixing. Insoluble material was removed by centrifugation (15,000 rpm for 15 min at 4 °C). Cleared lysates were incubated with streptavidin-agarose (40 µl of beads) for 5-6 h on ice with constant mixing. The streptavidin-agarose was pelleted and washed four times with the RIPA buffer. Precipitated proteins were eluted by boiling the beads in 50 µl of 2× SDS sample buffer for 10 min with intermittent agitation. A second round of streptavidin precipitation was carried out in some experiments. However, subsequent Western blotting with an anti-MARCO antibody demonstrated that practically no MARCO protein precipitated at this time, indicating that the first precipitation was quantitative. Therefore, the second precipitation was not carried out in every experiment.

Western Blotting-- Western blotting was carried out using established procedures. The rat monoclonal antibody 1.18, which recognizes an epitope within the cytoplasmic domain of MARCO (16), was used to probe the different forms of MARCO. The filters were stripped with 62.5 mM Tris-HCl, pH 6.8, 2% SDS, 100 mM 2-mercaptoethanol, before probing with an anti-paxillin monoclonal antibody.

Immunofluorescence-- For immunofluorescence analysis, cells grown on glass coverslips were fixed in 4% paraformaldehyde solution for 20 min at room temperature and then permeabilized in 0.1% Triton X-100/PBS for 5 min. After rinsing twice in PBS, free aldehyde groups were quenched by incubating cells in PBS containing 50 mM NH4Cl for 10 min. Thereafter, cells were incubated in PBS containing 2% bovine serum albumin (blocking solution). All antibodies were diluted in the blocking solution. When staining for MARCO, cells were incubated either with rat monoclonal antibody 1.18 or 7.21 (10 µg/ml) for 1-2 h. The epitope of the anti-MARCO antibody 7.21 is located in domain V (16). After rinsing several times in PBS, cells were incubated with FITC-labeled rabbit anti-rat IgG. Cells were rinsed again several times in PBS, and coverslips were mounted by inverting them into PBS containing 50% glycerol and 1 mg/ml p-phenylenediamine. For filamentous actin staining, rhodamine-conjugated phalloidin was added to the secondary antibody solution.

For double labeling for MARCO and paxillin, cells were fixed and permeabilized as above and then incubated for 2 h with mouse monoclonal antibody against paxillin (1 µg/ml). After several washes in PBS, cells were incubated with biotinylated rabbit anti-mouse IgG (5 µg/ml) for 30 min, rinsed again in PBS, and incubated with rhodamine-conjugated streptavidin for 20 min (5 µg/ml). After this, cells were fixed again in the paraformaldehyde solution and stained for MARCO as described above.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Expression of MARCO Induces Formation of Cellular Processes and Rearrangement of the Actin Cytoskeleton-- An interesting change in cell shape was noticed when cells not normally expressing MARCO were transfected with a plasmid encoding the full-length protein. When cells were grown overnight on glass coverslips in complete medium and examined by immunofluorescence microscopy about 40 h after transfection, MARCO-expressing cells often had processes with lengths several times the size of the cell body. Cell lines studied included CHO, HeLa, NIH3T3, and 293 cells. There was some variation in the morphological effects of MARCO between the cell lines so that the processes were longest in 293 cells and that the other cell lines mentioned above often also had large lamellipodia-type structures (from which the long processes extended). Examples of MARCO-expressing CHO and HeLa cells are shown in Fig. 1 (A, C, and D) and also in Figs. 6 and 7. In contrast, COS7 cells responded quite differently to MARCO transfection. In these cells, MARCO expression led to formation of short pine needle-like protrusions (not shown).


View larger version (27K):
[in this window]
[in a new window]
 
Fig. 1.   Expression of MARCO induces formation of long plasma membrane processes. CHO (A-C) and HeLa cells (D) were transiently transfected with an expression plasmid encoding the full-length MARCO and examined 40 h after transfection. Cells were double-stained for MARCO (FITC) and filamentous actin (rhodamine). Double-staining is shown in A, C, and D. B represents the same field as A but shows only the actin filament staining. MARCO-expressing cells are not stained as strongly as untransfected cells by rhodamine-conjugated phalloidin. This exposure does not reveal the weak phalloidin staining of the long processes.

Process formation was not dependent on the transfection method, since a similar effect was observed when MARCO-expressing DNA was introduced either by calcium-phosphate method or by retroviral infection (not shown). To test if the process formation was due to overexpression of a membrane protein, we expressed the H1 subunit of the human asialoglycoprotein receptor which is, similar to MARCO, a type II membrane protein. Expression of this protein did not induce any morphological changes (not shown), demonstrating that cell shape changes are not simply a consequence of expression of a cell membrane protein. In further studies, it turned out that MARCO-expressing cells could be identified in cell populations simply by staining for actin filaments (Fig. 1B). Compared with untransfected cells, MARCO-expressing cells stained only weakly by the filamentous actin-staining rhodamine-conjugated phalloidin. Furthermore, filamentous actin appeared to be organized differently in these two populations of cells. Examination of cells by a higher magnification revealed that untransfected cells had an organized actin cytoskeleton with numerous long stress fibers (Fig. 2). In contrast, the MARCO-expressing cells almost completely lacked stress fibers. Instead, there were fine actin filaments extending from the cell periphery into the processes, although the phalloidin staining was very weak in these processes (not shown). The processes were frequently heavily branched, and examination of the branching pattern revealed that these processes were "protrusive filopodia" instead of trailing tails, being left behind by migratory cells.


View larger version (79K):
[in this window]
[in a new window]
 
Fig. 2.   Effect of MARCO expression on distribution of filamentous actin. Untransfected CHO cells have an organized actin cytoskeleton with numerous stress fibers. A MARCO-expressing cell (lower left corner) appears to lack stress fibers. Instead, there are fine actin filaments protruding from cell periphery.

In order to study the early phases of the process formation, we focused on transiently transfected CHO cells, since these cells did not aggregate when held overnight in suspension. Cells were taken into suspension 24 h after transfection and were then plated 12-16 h later on FCS-coated coverslips. When cells were fixed 5 min after plating, all of them were round, and the MARCO-expressing ones were morphologically indistinguishable from untransfected cells (not shown). However, when cells were fixed 30 min after plating, untransfected cells were still fairly round, but most of the MARCO-expressing cells were already well spread (Fig. 3A). In addition, there were lamellipodia-like protrusions extending from the periphery of some of the MARCO-expressing cells (Fig. 3B). Examination of cells 1 h after plating revealed that most of the MARCO-expressing cells had protrusions (Fig. 3C). Furthermore, many of the cells sent out thin dendritic processes. After a few hours the processes could be several times longer than the cell body (3 h after plating in Fig. 3D). It is of interest to note that the cell spreading is fairly symmetrical and that forming lamellipodia appear to extend randomly in different directions. However, soon thereafter MARCO-expressing cells acquired polarity so that the long processes extended only from one pole of the cell.


View larger version (36K):
[in this window]
[in a new window]
 
Fig. 3.   Time course of MARCO-promoted cell shape changes. Transiently transfected CHO cells were taken into suspension 24 h after transfection and plated 16 h later on FCS-coated glass coverslips. Cells were fixed after 30 min (A and B), 1 h (C), or 3 h (D) and stained for MARCO (FITC) and actin filaments (rhodamine). When examined 30 min after plating, MARCO-expressing cells can already be distinguished from untransfected cells by their flatter appearance (A). Sometimes MARCO-expressing cells have extensive lamellipodia-type protrusions already at this time point (B). Lamellipodia-type protrusions extend randomly in different directions (B and C), whereas the long processes extend only from one of the protrusions (D). The arrow in B indicates lamellipodia.

The MARCO-induced morphological effects were efficiently inhibited when cells were plated on FCS-coated coverslips for 45 min in the presence of 2 µM cytochalasin D (not shown), demonstrating the crucial role of actin polymerization in this process (at a 2-h time point cytochalasin D was found to have a toxic effect). On the other hand, 10 mM butanedione monoxime, a known myosin inhibitor, did not have significant effects during the initial cell spreading, whereas it markedly inhibited the process formation (not shown). In this experiment, cells were assayed 45 min and 2 h after plating on FCS-coated coverslips.

Segment of Domain V Is Important for the Morphoregulatory Activity of MARCO-- In order to identify specific regions of the MARCO polypeptide required for the morphological effects, different truncated forms of MARCO were expressed in CHO cells (Fig. 4). First, we tested truncations M-436 and M-441, which almost completely lacked the C-terminal cysteine-rich domain V and contained, respectively, only the first 16 and 21 residues of this domain. Both forms effectively promoted the morphological change, demonstrating that most of the domain V is not needed for this activity. We next produced a version of MARCO that lacks the C-terminal half of the collagenous domain (version Bst, lacking residues 299-419), and the morphological change of cells was observed upon expression of this protein, too. Since this indicated that the C-terminal part of the collagenous domain is not needed for the morphological effects, we next tested a form of MARCO, whose extracellular part is composed of the first 4 residues of the spacer domain, the last 65 residues of the collagenous domain, and an intact domain V (version Eco). Somewhat surprisingly, this variant also promoted process formation, albeit not as efficiently as the other truncated forms. Taken together, the only region of the extracellular domain that is common for all these effective truncated versions is a segment of domain V before its first cysteine residue (residues 420-436). Therefore, we predicted that expression of the form M-419, which does not contain any segments of domain V, would not result in the change of the cell shape. Indeed, this was the case, indicating that the segment of domain V encompassing its first 15-20 residues is important for this activity. We tried to confirm this result by expressing a version of MARCO in which only this region is deleted (version Del 422-433). However, this protein did not appear on the cell surface (see below) but was apparently retained in the secretory pathway.


View larger version (8K):
[in this window]
[in a new window]
 
Fig. 4.   Schematic illustrations of the MARCO variants used in transfection experiments. M-419, M-436, and M-441 are C-terminal truncations. Bst, Eco, and Del422-433 contain internal deletions. The deleted regions are delineated by dashed lines and are additionally highlighted by hatch marks. cyto, cytoplasmic domain; TM, transmembrane domain; SRCR, scavenger receptor cysteine-rich domain (domain V); C, C-terminal end; N, N-terminal end; w.t., wild-type MARCO.

Since the truncation M-419 did not promote any morphological changes, we wanted to ensure that it was still expressed on the cell surface. In order to examine this, cells were biotinylated with a membrane-impermeable reagent sulfo-NHS-biotin, after which biotinylated proteins were precipitated by streptavidin-agarose and analyzed by Western blotting using an antibody recognizing the cytoplasmic domain of the MARCO protein. This experiment demonstrated that the form M-419 and the full-length MARCO were expressed at equal levels on the cell surface (not shown) and that some of the morphologically active truncations, such as M-436, are not as abundantly expressed on the cell surface (Fig. 5A). Moreover, along with the results obtained in the transfection studies with a plasmid encoding the H1 subunit of the human asialoglycoprotein receptor (see above), these results indicate that the morphological change is not a nonspecific effect, due only to overexpression of a cell-surface protein. In accordance with this conclusion, we have observed that cells change their morphology also when expression of MARCO is driven from a weak promoter, the minimal cytomegalovirus promoter (not shown). To confirm that only cell-surface proteins were labeled by sulfo-NHS-biotin, we wanted to verify that paxillin, a component of focal adhesions at the inner site of the plasma membrane, was not precipitated by streptavidin-agarose. This was the case, even though an anti-paxillin antibody gave a strong signal with the total cell lysate (Fig. 5B). Similarly, one of the MARCO truncations, Del 422-433, was not precipitated by streptavidin-agarose, although it was abundant in the total cell lysate. Thus, the absence of these two proteins, the MARCO form Del 422-433 and paxillin, in the streptavidin precipitates indicates that sulfo-NHS-biotin did not leak into cells during the course of the experiment.


View larger version (88K):
[in this window]
[in a new window]
 
Fig. 5.   Analyses of proteins in transiently transfected CHO cells. A, amounts of the different MARCO forms on the cell surface. Cell-surface proteins were biotinylated on ice followed by the precipitation with streptavidin-agarose. The precipitated proteins were analyzed by Western blotting using an anti-MARCO antibody recognizing the cytoplasmic domain (monoclonal antibody 1.18). CHO cells were transfected with expression vectors encoding forms Del422-433 (lane 1), M-419 (lane 2), M-436 (lane 3), and M-441 (lane 4). B, two of the samples analyzed in A, M-419 and M-436, were also analyzed for the presence of paxillin in the streptavidin precipitate. Lane 1, total cell lysate from cells expressing the form M-419 (1/100 portion of the total lysate); lane 2, total cell lysate from cells expressing the form M-436 (1/100 portion). Lanes 3 and 4 represent streptavidin precipitates and show that paxillin was not precipitated by streptavidin-agarose, indicating that only cell-surface proteins were biotinylated during the course of the experiment. One-quarter of the precipitated proteins were loaded in the gel.

Taken together, these results demonstrate that the MARCO-induced morphological change is not a nonspecific effect due to overexpression of a cell-surface protein and that the region of domain V before its first cysteine residue is important for this activity of MARCO.

Effects of MARCO Expression on the Formation of Focal Adhesions-- The observation that actin filaments were rearranged in the MARCO-expressing cells (Fig. 2) raised the question whether these cells still have intact focal adhesions. To examine this, transiently transfected CHO and HeLa cells were plated on glass coverslips 24 h post-transfection and were fixed and double-labeled for MARCO and endogenous paxillin 16 h later. The staining revealed that MARCO-expressing CHO cells with extensive processes do not have focal adhesions (not shown). MARCO-expressing CHO cells with short processes have some kind of focal adhesions, but they are not well formed compared with focal adhesions in untransfected cells (Fig. 6, A and B). There are no focal adhesions in the cellular processes. Furthermore, it appears that focal adhesions do not follow the margins of the cell body, indicating that the MARCO-induced lamellipodia-like structures are devoid of focal adhesions. The same also holds true for MARCO-expressing HeLa cells, as shown in Fig. 6, C and D.


View larger version (92K):
[in this window]
[in a new window]
 
Fig. 6.   Effects of MARCO expression on focal adhesion assembly. CHO (A and B) and HeLa cells (C and D) transiently expressing MARCO were double-stained for MARCO (A and C) and endogenous paxillin (B and D). A and B and C and D, respectively, represent the same field. Cells were examined 40 h post-transfection, after growing them for 16 h on glass coverslips. Focal adhesions do not follow cell margins in the MARCO-expressing cells. Note that CHO cells (B) not expressing MARCO have distinct paxillin-positive focal adhesions (arrows). It is not shown here, but often there are no focal adhesions in those MARCO-expressing cells that have very long extensions, or, as shown in B, if there are focal adhesions, they are not necessary well formed.

Effects of Different ECM Substrata on the Formation of the Long Plasma Membrane Processes-- To examine the effects of different substrata on the MARCO-induced cell shape changes, cells were plated on coverslips precoated with FCS or with purified ECM components laminin-1, vitronectin, and fibronectin. As a comparison, cells were plated on uncoated glass. Transiently transfected CHO cells kept in suspension overnight were plated in serum-free medium, and cells were fixed and stained for MARCO and actin filaments 3 h later. This staining showed that extensions on the MARCO-expressing cells were longest when cells were plated on uncoated glass and that plating on different ECM components did not prevent formation of the extensions. However, they were clearly much shorter on the fibronectin-coated surface (not shown). On that surface, both untransfected and MARCO-expressing cells spread extensively.

Dominant-Negative Rac1 Inhibits the Morphological Effects of MARCO in CHO Cells-- Small GTPases of the Rho family have been shown to control rearrangement of the actin cytoskeleton (17). Specifically, activated Cdc42 promotes formation of filopodia, whereas the activated form of Rac1 induces cell spreading and lamellipodia formation. Since the MARCO-induced cell shape changes somewhat resemble the phenotypic changes caused by activated Cdc42 and Rac1, we investigated whether these GTPases play any role in the MARCO-induced cell spreading/process formation. In order to study this, we co-expressed MARCO and dominant-negative forms of Cdc42 and Rac1 in CHO cells (Fig. 7). Transiently transfected CHO cells were taken into suspension 24 h after transfection and were plated 12 h later on FCS-coated coverslips. Cells were fixed after 30 min, since it was known that the MARCO-expressing cells are already extensively spread at this time point (Fig. 3A). Cells co-expressing MARCO and dominant-negative Cdc42 did not differ morphologically from the MARCO-expressing cells. In contrast, dominant-negative Rac1 markedly inhibited the MARCO-induced cell spreading (not shown). We also examined cells that were plated on coverslips for 16 h. Again, dominant-negative Cdc42 did not have inhibitory activity (Fig. 7B), but Rac1V12N17 clearly inhibited the MARCO-induced morphological changes (Fig. 7, C and D). However, Rac1V12N17 did not completely abolish the MARCO-induced effects. There were a few large MARCO-positive cells but no cells with long processes. The dominant-negative forms of Cdc42 and Rac1 contain a Myc epitope tag at their N termini, and analysis of total cell lysates by Western blotting using an anti-Myc antibody demonstrated that these GTPase mutants were produced at equal levels (Fig. 7F).


View larger version (57K):
[in this window]
[in a new window]
 
Fig. 7.   Dominant-negative Rac1 inhibits the MARCO-induced process formation in CHO cells. CHO cells were transfected with a plasmid encoding MARCO together with either an empty expression vector, an expression vector encoding a Myc-tagged dominant-negative form of Cdc42, Cdc42N17, or with an expression vector encoding a Myc-tagged dominant-negative form of Rac1, Rac1V12N17. A-D, cells were seeded on glass coverslips 24 h post-transfection and were fixed and stained for MARCO and filamentous actin 36 h after transfection. The photos represent the following transfections: MARCO + empty vector (A), MARCO + Cdc42N17 (B), and MARCO + Rac1V12N17 (C and D). The dominant-negative Rac1 significantly inhibits the MARCO-induced process formation. E and F, cells were grown on tissue culture plates and were analyzed 40 h post-transfection. E, cell-surface level of MARCO was examined as described under "Experimental Procedures" and in Fig. 5. The lanes represent the following transfections: MARCO + Rac1V12N17 (lane 1), MARCO + Cdc42N17 (lane 2), and MARCO + empty vector (lane 3). F, total cell lysates were analyzed by Western blotting for the presence of the GTPase mutants using an anti-Myc antibody. Results from two different transfection experiments are shown. The lanes represent the following transfections: MARCO + Rac1V12N17 (lanes 1 and 4), MARCO + Cdc42N17 (lanes 2 and 5), and MARCO + empty vector (lanes 3 and 6). The results shown in E and F demonstrate that different cotransfectants express similar levels of MARCO on the cell surface (E) and that both of the GTPase mutants are expressed at high levels (F).

One possible explanation for the different phenotypic effects of the dominant-negative Rac1 and Cdc42 was that MARCO/Rac1V12N17 transfectants expressed MARCO at lower levels than MARCO/Cdc42N17 transfectants. In order to study if this was the case, we analyzed the cell-surface levels of MARCO using the biotinylation/streptavidin-agarose precipitation procedure followed by Western blotting using an anti-MARCO antibody. In three different experiments the MARCO/Rac1V12N17 transfectants were found to have at least as much MARCO on the cell surface as the MARCO/Cdc42N17 transfectants (Fig. 7E). These results demonstrate that the phenotypic effects of dominant-negative Rac1 are not simply due to an inhibitory effect on the cell-surface expression of MARCO. As in previous studies, we confirmed that the biotinylation reagent labeled only cell-surface proteins by using an anti-paxillin antibody (not shown).

    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

In this study, we have shown that expression of the macrophage MARCO receptor results in extensive changes in cell morphology through induction of dendritic plasma membrane processes. Of the five cell lines tested, COS7 cells were the only exception, since in these cells MARCO expression had minor morphological effect by leading to the formation of short pine needle-like protrusions. The reason for this different response is unclear, but it could be related to the strength of adhesion between cells and serum-coated surface. Supporting this notion, we found that processes were longest in 293 cells, which are weakly adhering cells, whereas COS7 cells spread well and adhere tightly to serum-coated glass surface.

Several lines of evidence indicate that the morphological effects are specific effects of the MARCO receptor itself. By using various truncated forms of MARCO, it was shown that the part of domain V before its first cysteine residue is needed for this activity. This conclusion is based, for example, on the following two observations. First, a MARCO form completely lacking domain V did not have any effect on cell morphology, although it was expressed at high levels on the cell surface. Second, a form that extends only 16 residues to domain V was found to be about as active as the full-length MARCO. In a previous study, we showed that when cells are transfected with expression vectors encoding these two forms, only cells expressing the longer form bind heat-killed bacteria (7). This result is another indication that the region of domain V proximal to the collagenous domain is functionally important in MARCO. Our previous work also suggested that this region is exposed on the MARCO protein since it was very sensitive for proteolysis when expressed as a fusion protein (7).

It remains to be investigated whether the cytoplasmic domain and/or the transmembrane domain are also needed for the morphological activity of MARCO. Thus far, we have tested a truncated form lacking the N-terminal half of the cytoplasmic domain, and the morphological effects are not abolished. The use of chimeric proteins is needed to determine the role of these domains, since MARCO is a type II membrane protein, and the membrane-proximal region, which contains several positively charged residues, is very likely important for a correct topological orientation of MARCO.

MARCO was shown to induce process formation on different surfaces, such as uncoated glass, laminin-1, and vitronectin. In fact, the processes were longest when the cells were plated in serum-free media on uncoated glass. Of the purified ECM components tested, fibronectin was the only protein that clearly had an inhibitory effect on the MARCO-induced process formation. Thus, cell adhesion on fibronectin and MARCO expression seem to have opposite effects on the organization of the actin cytoskeleton. Indeed, cell adhesion on fibronectin has been reported to promote rapid actin stress fiber and focal adhesion formation (18), whereas the present study shows that expression of MARCO promotes dissolution of stress fibers and focal adhesions.

It is not yet known whether MARCO binds glass or different ECM proteins. We are currently producing a soluble MARCO for the binding studies. In this context, it is noteworthy that a protein related to MARCO, macrophage scavenger receptor A, has been shown to function as an adhesion receptor, whose ligand is present in fetal calf serum (14). Interestingly, thioglycollate-elicited peritoneal macrophages from MSR-A knock-out mice have also been found to spread on glass slower than wild-type macrophages (13). It is, however, possible that MARCO exerts its effects by interacting with another cell-surface protein expressed on the same cell, as was found to be the case for integrin alpha 6Abeta 1 in embryonic stem cells. In these cells expression of alpha 6Abeta 1 integrin induces changes in the morphology (filopodia formation) and migration without having to engage with its ECM ligand (19). Instead, the alpha 6Abeta 1-induced motility appears to depend on the association of alpha 6Abeta 1 with CD81, a member of the tetraspanin superfamily of cell-surface molecules (19).

Dominant-negative Rac1 partially inhibited the MARCO-induced cell shape changes in CHO cells. We believe that this is not due to nonspecific toxic effects since these cells were still capable of functioning normally, at least if judged by the amount of MARCO they produced and transported to the cell surface. The partial inhibition suggests that exogenous dominant-negative Rac1 could not completely inhibit the activity of the endogenous Rac1 or Rac1-related protein. On the other hand, it is known that activated Rac1 causes a phenotype that differs from that induced by MARCO. It promotes cell spreading and formation of lamellipodia but does not induce formation of long plasma membrane processes. Thus, the Rac1 pathway is not the only pathway activated by MARCO. Surprisingly, dominant-negative Rac1 did not have any effect on MARCO-induced cell shape changes in HeLa cells. We do not know the reason for this, but it is conceivable that MARCO activates some Rac1-related protein in these cells and that dominant-negative Rac1 is not able to interfere with the activity of this protein.

Several protein kinases, such as p21 (Cdc42/Rac)-activated kinase aPAK, have been shown to play a role either in the formation or dissolution of stress fibers and focal adhesions (18, 20). Also, lipid kinases have been shown to be involved in the actin remodeling. For example, expression of type I phosphatidylinositol-4-phosphate 5-kinase induces formation of pine needle-like protrusions in COS7 cells (21). Interestingly, these protrusions resemble those induced by MARCO expression in COS7 cells. The effects of phosphatidylinositol-4-phosphate 5-kinase on cell morphology are most likely due to elevated levels of phosphatidyl 4,5-biphosphate which is able to uncap actin filament barbed ends, thereby promoting actin polymerization (22). Recent evidence also suggest that the Rho family GTPases are able to regulate phosphatidyl 4,5-biphosphate levels. For example, Rac was shown to induce rapid synthesis of phosphatidyl 4,5-biphosphate in permeabilized platelets (22).

Our efforts to elucidate the signaling pathways activated by MARCO have been partly hampered by the lack of a population of cells uniformly expressing MARCO. CHO transfectants appear to lose most of their MARCO-expressing cells during their propagation. It is possible that the morphological effects of MARCO hinder cell division, and we wish to overcome this problem by the use of an inducible expression system.

MARCO is expressed constitutively only in macrophages in lymph nodes and marginal zone of the spleen (3). The marginal zone macrophages are thought to be important in the trapping and clearance of microorganisms from the bloodstream (23). Our results indicate that MARCO has several functions that contribute to this activity of the marginal zone macrophages. First of all, as shown previously (3, 7), MARCO is able to bind bacteria. Second, the morphoregulatory activity resulting in the formation of large lamellipodia-like structures and long plasma membrane extensions provides an enlarged cell-surface area. This, in turn, facilitates efficient trapping of pathogens by cell-surface receptors.

    ACKNOWLEDGEMENTS

We are grateful to J. Engel, A. Hall, G. Kraal, M. Spiess, and L. van der Laan for their generous gifts of reagents. We thank Ulrich Bergmann, Outi Elomaa, Antti Iivanainen, and Ari Tuuttila for helpful discussions during the course of this investigation. We thank Ulrich Bergmann and Raija Soininen for their comments on the manuscript. We also thank Jarkko Kortesmaa and Marko Sankala for help in preparation of the figures.

    FOOTNOTES

* This work was supported in part by grants from the Swedish Natural Science Research Council, the Foundation for Strategic Research, and Hedlund's Foundation.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger To whom correspondence should be addressed: Division of Matrix Biology, Dept. of Medical Biochemistry, Karolinska Institutet, S-171 77 Stockholm, Sweden. Tel.: 46-8-728-7720; Fax: 46-8-316165; E-mail: karl.tryggvason{at}mbb.ki.se.

    ABBREVIATIONS

The abbreviations used are: MARCO, macrophage receptor with collagenous structure; CHO, Chinese hamster ovary cells; MSR, macrophage scavenger receptor; FCS, fetal calf serum; ECM, extracellular matrix; PBS, phosphate-buffered saline; FITC, fluorescein isothiocyanate, M-419, M-436, M-441, recombinant MARCO receptor variants containing 419, 436, and 441 residues, respectively, from the N-terminal end.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES
  1. Fawcett, D., and Raviola, E. (1994) in A Textbook of Histology (Fawcett, D., and Bloom, W., eds), 12th Ed., pp. 150-155, Chapman & Hall, New York, London
  2. Kuby, J. (1997) in Immunology (Kuby, J., ed), 3rd Ed., pp. 64-67, W. H. Freeman and Co., New York
  3. Elomaa, O., Kangas, M., Sahlberg, C., Tuukkanen, J., Sormunen, R., Liakka, A., Thesleff, I., Kraal, G., and Tryggvason, K. (1995) Cell 80, 603-609[Medline] [Order article via Infotrieve]
  4. van der Laan, L. J. W., Kangas, M., Döpp, E. A., Broug-Holub, E., Elomaa, O., Tryggvason, K., and Kraal, G. (1997) Immunol. Lett. 57, 203-208[CrossRef][Medline] [Order article via Infotrieve]
  5. Kodama, T., Freeman, M., Rohrer, L., Zabrecky, J., Matsudaira, P., and Krieger, M. (1990) Nature 343, 531-535[CrossRef][Medline] [Order article via Infotrieve]
  6. Rohrer, L., Freeman, M., Kodama, T., Penman, M., and Krieger, M. (1990) Nature 343, 570-572[CrossRef][Medline] [Order article via Infotrieve]
  7. Elomaa, O., Sankala, M., Pikkarainen, T., Bergmann, U., Tuuttila, A., Raatikainen-Ahokas, A., Sariola, H., and Tryggvason, K. (1998) J. Biol. Chem. 273, 4530-4538[Abstract/Free Full Text]
  8. Freeman, M., Ekkel, Y., Rohrer, L., Penman, M., Freedman, N. J., Chisolm, G. M., and Krieger, M. (1991) Proc. Natl. Acad. Sci. U. S. A. 88, 4931-4935[Abstract]
  9. Hampton, R. Y., Golenbock, D. T., Penman, M., Krieger, M., and Raetz, C. R. H. (1991) Nature 352, 342-344[CrossRef][Medline] [Order article via Infotrieve]
  10. Dunne, D. W., Resnick, D., Greenberg, J., Krieger, M., and Joiner, K. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 1863-1867[Abstract]
  11. Krieger, M., and Herz, J. (1994) Annu. Rev. Biochem. 63, 601-637[CrossRef][Medline] [Order article via Infotrieve]
  12. Haworth, R., Platt, N., Keshav, S., Hughes, D., Darley, E., Suzuki, H., Kurihara, Y., Kodama, T., and Gordon, S. (1997) J. Exp. Med. 186, 1431-1439[Abstract/Free Full Text]
  13. Suzuki, H., et al.. (1997) Nature 386, 292-296[CrossRef][Medline] [Order article via Infotrieve]
  14. Fraser, I., Hughes, D., and Gordon, S. (1993) Nature 364, 343-345[CrossRef][Medline] [Order article via Infotrieve]
  15. Schneider, G., and Burridge, K. (1994) Exp. Cell Res. 214, 264-269[CrossRef][Medline] [Order article via Infotrieve]
  16. van der Laan, L. J. W., Döpp, E. A., Haworth, R., Pikkarainen, T., Kangas, M., Elomaa, O., Dijkstra, C. D., Gordon, S., Tryggvason, K., and Kraal, G. (1999) J. Immunol. 162, 939-947[Abstract/Free Full Text]
  17. Hall, A. (1998) Science 279, 509-514[Abstract/Free Full Text]
  18. Burridge, K., and Chrzanowska-Wodnicka, M. (1996) Annu. Rev. Cell Dev. Biol. 12, 463-519[CrossRef][Medline] [Order article via Infotrieve]
  19. Domanico, S. Z., Pelletier, A. J., Havran, W. L., and Quaranta, V. (1997) Mol. Biol. Cell 8, 2253-2263[Abstract/Free Full Text]
  20. Lim, L., Manser, E., Leung, T., and Hall, C. (1996) Eur. J. Biol. Chem. 242, 171-185
  21. Shibasaki, Y., Ishihara, H., Kizuki, N., Asano, T., Oka, Y., and Yazaki, Y. (1997) J. Biol. Chem. 272, 7578-7581[Abstract/Free Full Text]
  22. Hartwig, J. H., Bokoch, G. M., Carpenter, C. L., Janmey, P. A., Taylor, L. A., Toker, A., and Stossel, T. P. (1995) Cell 82, 643-653[Medline] [Order article via Infotrieve]
  23. Kraal, G. (1992) Int. Rev. Cytol. 132, 31-74[Medline] [Order article via Infotrieve]


Copyright © 1999 by The American Society for Biochemistry and Molecular Biology, Inc.